Effects of mesenchymal stromal cells versus serum on tendon healing in a controlled experimental trial in an equine model by Ahrberg, A B et al.
RESEARCH ARTICLE Open Access
Effects of mesenchymal stromal cells versus
serum on tendon healing in a controlled
experimental trial in an equine model
A. B. Ahrberg1,2*†, C. Horstmeier2,3,4†, D. Berner5, W. Brehm2,3,4, C. Gittel4, A. Hillmann2,3, C. Josten1, G. Rossi6,
S. Schubert2,3,7, K. Winter4,8 and J. Burk2,3,7,9
Abstract
Background: Mesenchymal stromal cells (MSC) have shown promising results in the treatment of tendinopathy in
equine medicine, making this therapeutic approach seem favorable for translation to human medicine. Having
demonstrated that MSC engraft within the tendon lesions after local injection in an equine model, we
hypothesized that they would improve tendon healing superior to serum injection alone.
Methods: Quadrilateral tendon lesions were induced in six horses by mechanical tissue disruption combined with
collagenase application 3 weeks before treatment. Adipose-derived MSC suspended in serum or serum alone were
then injected intralesionally. Clinical examinations, ultrasound and magnetic resonance imaging were performed
over 24 weeks. Tendon biopsies for histological assessment were taken from the hindlimbs 3 weeks after treatment.
Horses were sacrificed after 24 weeks and forelimb tendons were subjected to macroscopic and histological
examination as well as analysis of musculoskeletal marker expression.
Results: Tendons injected with MSC showed a transient increase in inflammation and lesion size, as indicated by
clinical and imaging parameters between week 3 and 6 (p < 0.05). Thereafter, symptoms decreased in both groups
and, except that in MSC-treated tendons, mean lesion signal intensity as seen in T2w magnetic resonance imaging
and cellularity as seen in the histology (p < 0.05) were lower, no major differences could be found at week 24.
Conclusions: These data suggest that MSC have influenced the inflammatory reaction in a way not described in
tendinopathy studies before. However, at the endpoint of the current study, 24 weeks after treatment, no distinct
improvement was observed in MSC-treated tendons compared to the serum-injected controls. Future studies are
necessary to elucidate whether and under which conditions MSC are beneficial for tendon healing before
translation into human medicine.
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Background
In orthopedic surgery and sports medicine, tendinopathy
has become one of the most challenging conditions. Achil-
les tendinopathy, for example, is a growing problem with a
high incidence [1]. Various therapies have been tried with-
out lasting success [2–8]. This underlines the need for a
new curative therapy from the field of regenerative medi-
cine. The horse, which could be referred to as animal ath-
lete, suffers from a natural tendinopathy in its superficial
digital flexor tendon (SDFT) which is similar to the Achil-
les tendon in its structure, function and pathophysiology
[9–12]. Therefore, horses are considered as highly suitable
model animals for orthopedic research and have been
recommended by authorities such as the U.S. Food and
Drug Administration (FDA) and the European Medicines
Agency (EMA) [13, 14]. Contrary to human medicine,
regenerative cell therapies have already been used in
equine medicine for more than a decade, with most
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experiences in multipotent mesenchymal stromal cells
(MSC) therapy for tendon disease [15]. Clinical
results are promising, although the mechanisms of
action leading to improved tendon healing are not yet
fully understood [11, 16, 17].
MSC are adult progenitor cells displaying plastic-adhere-
nce and multipotent differentiation potential in vitro and
can be further characterized by a set of surface marker anti-
gens [18]. They can be extracted from various tissues, e.G.
adipose tissue or bone marrow and are thought to support
tissue regeneration not only by cell replacement, but also
via trophic and modulatory effects which are mediated by
cell-cell contact or paracrine mechanisms [19–21].
The promising results of MSC therapy in equine patients
make a translation into human medicine appear reasonable.
Recently we were able to show that adipose-derived MSC
engrafted within tendon lesions after local injection in an
equine model although there was also systemic distribution
of a small number of cells [22]. These results were obtained
on the basis of labeling the MSC with superparamagnetic
iron oxide (SPIO) and rhodamine. After demonstrating
long-term MSC persistence we aimed to evaluate the effect
of these MSC on tendon healing within the same set of ani-
mals as presented in the current study. We hypothesized
that local injection of adipose-derived MSC improves out-
come parameters obtained by clinical imaging and histo-
logical assessment as well as gene expression analysis over
a follow-up period of 24 weeks.
Methods
Study design
Tendinopathy of the SDFT was induced in all limbs of 6
horses and autologous adipose tissue was harvested
(week − 3). MSC were expanded and labeled with SPIO.
MSC resuspended in serum or serum alone were
injected into the left and right tendon lesions 3 weeks
after their induction (week 0). Clinical examinations and
diagnostic imaging were performed over 24 weeks (week
0, 1, 2, 3, 4, 6, 8, 12 and 24). Tendon biopsies were taken
after 3 weeks from the hindlimb SDFT for early histo-
logical evaluation (week 3). After euthanasia at week 24,
forelimb SDFT were harvested for macroscopic and late
histological evaluation and for analysis of musculoskel-
etal marker expression. Approval of the local ethics
committee (TVV 34/13) had been given beforehand.
Animals
Six horses (standardbred; mean age: 6 years; age range:
3–10 years; 3 female, 3 male; body weight: 400–550 kg)
were included in the study. The horses were obtained
from trot racing courts in accordance with the local au-
thority. Clinical evaluation, ultrasound (US) and Mag-
netic Resonance Imaging (MRI) of all extremities were
performed prior to the first surgery to ensure the
animals were healthy. The horses were housed in the
hospital’s stables. All procedures were performed within
the facility, so no transport of the horses was needed.
Induction of tendinopathy and adipose tissue collection
Tendinopathy was induced by minor mechanical tissue
disruption combined with a low-dose injection of colla-
genase type I (4.8 mg/mL, Life Technologies GmbH,
Darmstadt, Germany) in the SDFT of all 4 extremities
under general anesthesia (week − 3). With the horse
placed in lateral position, the skin was clipped and pre-
pared aseptically. An 11-gauge bone marrow aspiration
needle was introduced into the SDFT in the middle of
the metatarsal/metacarpal region via a skin incision.
0.4 mL collagenase type I (250 IU per tendon lesion)
were injected while removing the needle from 2 cm
proximal to 1 cm proximal from its entry point without
further damage of the epitenon. The incisions in the
peritendineum and skin were closed by suture and a
dressing was applied. Subcutaneous adipose tissue was
obtained from the supragluteal region of the horse in
the same surgery. The same orthopedic surgeon per-
formed all surgeries.
Post-surgery regime
After induction of tendinopathy, horses were restricted
to stall rest for 5 weeks (2 weeks after MSC injection)
and then managed according to the rehabilitation proto-
col previously described [23].
The horses were checked 3 times a day using stan-
dardized pain scores until 10 days post-surgery. For pain
relief, they received flunixin-meglumine (CP-Pharma
Handelsgesellschaft mbH, Burgdorf, Germany), 1.1 mg/
kg bwt twice daily on the day of surgery and 0.55 mg/kg
bwt twice daily on day 1 to 4 post surgery, followed by
0.55 mg/kg once daily on day 5 and 6, as well as add-
itional single 1.1 mg/kg bwt doses when required ac-
cording to pain scoring results.
Cell isolation and injection
The adipose tissue was subjected to cell isolation by colla-
genase digestion and plastic-adherent cells were isolated
and expanded as described previously [24]. The cells were
cultivated in a standard culture medium with Dulbecco’s
Modified Eagle’s Medium (DMEM, Life Technologies
GmbH, Darmstadt, Germany), 20% Fetal Bovine Serum
(FBS, Sigma-Aldrich Chemie GmbH, Steinheim, Germany),
1% Penicillin (10.000 IE/ml)/Streptomycin (10.000 μg/ml,
Life Technologies GmbH, Darmstadt, Germany) and 0,1%
Gentamicin (50 mg/ml, Life Technologies GmbH, Darm-
stadt, Germany). At passage 2 and 80% confluency, MSC
were labeled with SPIO particles (Molday ION Rhodamine
B™, BioPAL, Inc.™, Worcester, MA, USA) at 25 μg Fe per
ml for 20 h and harvested. Part of the cells from each
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animal was used to confirm MSC characteristics such as
trilineage differentiation and expression of CD29, CD44,
CD90 and CD105 as described before [24, 25].
Three weeks after lesion induction (week 0), the
freshly harvested and labeled MSC were injected into
the lesions under ultrasonographic guidance. Horses
were sedated and received an ulnar nerve block (fore-
limbs) or a high plantar nerve block (hindlimbs) with
additional local anesthesia (Lidocain 2%, bela-pharm
GmbH & Ko. KG, Vechta, Germany). With the horses
standing, the skin was clipped and prepared aseptically.
In a randomized manner, one hindlimb and one forelimb
were injected with MSC (107 cells in 1 ml autologous
serum) and the contralateral side with 1 ml autologous
serum. All injections were performed in a standardized
procedure by the same veterinary surgeon blinded to the
content of the syringes.
Clinical and imaging evaluation
Two veterinarians blinded for the treatment performed
all examinations in a standardized procedure.
Clinical parameters comprised a palpation score and a
lameness score. The palpation score included diffuse and
local swelling, heat and pain to palpation, the total score
points ranging from 4 (normal) to 16 (severe). The lame-
ness score included weight bearing/lameness when
standing, walking, trotting, and turning, the total score
points ranging from 7 (normal) to 29 (severe).
Ultrasonographic examinations of the SDFT were
performed using a 10 MHz linear transducer (LOGIQ 5
Expert, GE Healthcare, Munich, Germany) with a stand-
off probe. The SDFT was divided into zones and at least
one transverse and one longitudinal image was recorded
at every level [26]. Echogenicity of the lesion, peritendi-
nous edema and fiber pattern were evaluated for each
zone by 2 blinded observers in consensus, using a semi
quantitative score [27]. Furthermore, the cross-sectional
areas of the tendon lesion and the whole tendon were
measured in each transverse image and used to calculate
the percentage of the tendon lesion.
MRI of the SDFT region was performed in the stand-
ing sedated horse using a 0.27 Tesla dedicated equine
low-field MRI system (Hallmarq EQ2, Hallmarq Veterin-
ary Imaging, Guildford, Surrey, UK). T2-weighted (T2w)
fast spin echo sequences acquired in transverse plane at
weeks 0, 3, 12 and 24 were used to determine lesion signal
and lesion areas. Lesion volume was approximated by
multiplying the sum of the lesion areas in all images by
6 mm (5 mm slice thickness + 1 mm gap). Image process-
ing was performed using Mathematica (Wolfram Research,
Inc., Mathematica, Version 10.3.0.0, Champaign, IL). Ten-
don regions were manually drawn onto the images and
converted into binary image masks. Background-corrected
MRI images were segmented, and segmentations were
multiplied with the corresponding binary image masks to
detect lesion areas within the tendons. Positive regions in
the resulting binary images were smoothed and final binary
lesion masks were obtained. Grayscale values for tendon
and lesion regions were extracted from the background-
corrected images using the generated masks.
For all parameters obtained from ultrasonographic im-
ages as well as lesion signal intensity obtained from MRI
images, mean values of images obtained from the differ-
ent tendon levels were calculated and used for further
analysis, in order to account for the proximo-distal di-
mensions of the lesions.
Collection of tendon samples
Three weeks after MSC injection, tendon biopsies of the
maximum lesion, which had been identified by MRI be-
fore, were taken from the hindlimbs under general
anesthesia. The tendon was approached via a skin incision
of 3 cm and 0.2 × 0.3 × 2 cm tendon tissue was collected
and fixed in paraformaldehyde (Carl Roth, Karlsruhe,
Germany) for histological examination. Tendon, peritendi-
neum, subcutis and skin were sutured, and dressings were
applied. Post-operative management and pain medication
were performed as described above. After taking this bi-
opsy, the hindlimbs were excluded from all further
assessments.
24 weeks after MSC injection, the animals were eutha-
nized in general anesthesia using Romifidin 0,06 mg/kg
bwt i.v. (Sedivet®, 10 mg/ml, Boehringer Ingelheim Vet-
medica GmbH, Ingelheim am Rhein, Germany) and
Butorphanol 0,03 mg/kg bwt i.v (Alvegesic®, 10 mg/ml,
CP-Pharma Handelsgesellschaft mbH, Burgdorf,
Germany) for sedation, Diazepam 0,08 mg/kg bwt i.v.
(Diazepam-® Lipuro, 5 mg/ml, B. Braun Melsungen AG,
Melsungen, Germany) and Ketamin 2,2 mg/kg bwt i.v
(Ursotamin®, 100 mg/ml, Serumwerk Bernburg AG,
Bernburg, Germany) for the induction of anesthesia and
T61® 6 ml/50 kg bwt i.v. (Intervet Deutschland GmbH,
Unterschleißheim, Germany) for euthanasia. The whole
metacarpal region of both forelimb SDFT was collected.
First, macroscopic evaluation was performed, at which
all parameters (swelling, edema, adhesions, redness)
were summarized in a score ranging from 0 (normal) to
15 (severe). Afterwards, the tendons were sectioned into
2 cm long pieces, of which the lateral part was fixed in
paraformaldehyde for histological examination and the
medial part was frozen for gene expression analysis.
Histology
For histological examination, 3 μm paraffin sections were
prepared from the hindlimb biopsies and from the fore-
limb tendons, stained and assessed as described below.
Regarding the forelimb tendons, unless stated otherwise,
mean values were calculated from all dissected tendon
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pieces, representing the whole metacarpal region includ-
ing proximal and distal healthy areas, for further analysis.
The parameters evaluated in hematoxylin-eosin (HE)
staining were polymorphonuclear leukocytes, lympho-
cytes, macrophages, perivasculitis, necrosis, edema, cal-
cification, collagen disposition, fibrinosis and fiber
organization. The microscopic assessment was done by a
blinded veterinary pathologist, the score ranging from 0
(normal) to 30 (severe) as described before [28].
Masson’s Trichrome staining was used for evaluation
of the percentage of Fuchsin staining corresponding to
uninjured or regenerated tendon regions [29]. The per-
centages of Fuchsin-stained red areas were measured
based on whole slide scans obtained in a slide scanner
(Pannoramic SCAN, 3DHISTECH, Budapest, Hungary).
Red and blue color channels were extracted from the ac-
quired images and respective stained regions were seg-
mented by the Kittler-Illingworth minimum error
thresholding method using Mathematica software [30].
Picrosirius red staining and polarized light microscopy
were used to assess the occurrence of crimp. Three im-
ages from randomly chosen fields of view were obtained
per slide using a 10× objective (Olympus BX41 Labora-
tory microscope equipped with a U-pot drop in
polarizer; Olympus GmbH, Hamburg, Germany). The
percentages of large crimp (> 15 μm distance) represent-
ing healthy, mature crimp, or small and no crimp (<
15 μm distance) representing immature or missing
crimp were measured manually by 2 blinded investiga-
tors using ImageJ open source software.
DAPI (4′,6-diamidino-2-phenylindole, Carl Roth
GmbH + Co. KG, Karlsruhe, Germany) nuclear staining
was used to evaluate cellularity based on the nucleated
cell fraction. Whole slide scans from the maximum le-
sion levels were obtained in the slide scanner evaluated
in analogy to the Masson’s Trichrome stained slides. The
occurrence of nucleated cells represented by the per-
centage of blue staining (DAPI filter channel) was deter-
mined relative to the total area of each section.
Similarly, as an indicator for vascularization, the occur-
rence of erythrocytes was calculated as the percentage of
red fluorescence (Rhodamine filter channel), represent-
ing erythrocyte autofluorescence, per total section area.
Collagen I immunohistochemical staining was per-
formed on representative sections from the proximal le-
sion, maximum lesion, and distal lesion for each forelimb
tendon and one section of each hindlimb biopsy. Staining
was done with anti-collagen I antibody (rabbit polyclonal,
Abcam, Cambridge, UK) and a detection kit (EXPOSE
Mouse and Rabbit Specific AP, Abcam) according to the
manufacturer’s instructions. Two blinded investigators
evaluated the absence or presence of collagen I with 0
representing absence, 1 representing mild and 2 represent-
ing marked presence of immunostaining.
Musculoskeletal marker expression
Musculoskeletal marker expression was analyzed by
real-time reverse-transcription polymerase chain reac-
tion (RT-PCR) in each forelimb tendon sample piece.
Table 1 Primers used for RT-PCR analysis of musculoskeletal marker expression
Gene Primer pair sequences GenBank accession number PCR product in bp
ACTB For: ATCCACGAAACTACCTTCAAC NM_001081838.1 174
Rev: CGCAATGATCTTGATCTTCATC
GAPDH For: TGGAGAAAGCTGCCAAATACG NM_001163856.1 309
Rev: GGCCTTTCTCCTTCTCTTGC
Collagen 1A2 For: CAACCGGAGATAGAGGACCA XM_001492939.1 243
Rev: CAGGTCCTTGGAAACCTTGA
Collagen 2A1 For: ATTGTAGGACCCAAAGGACC XM_001496152 199
Rev: CAGCAAAGTTTCCACCAAGG
Collagen 3A1 For: AGGGGACCTGGTTACTGCTT XM_001917620.2 216
Rev: TCTCTGGGTTGGGACAGTCT
Decorin For: ACCCACTGAAGAGCTCAGGA NM_001081925.2 239
Rev: GCCATTGTCAACAGCAGAGA
Tenascin-C For: CTAGAGTGTCTCACTATCAGG XM_001916622.2 163
Rev: CTAGAGTGTCTCACTATCAGG
Scleraxis For: TACCTGGGTTTTCTTCTGGTCACT NM_001105150.1 51
Rev: TATCAAAGACACAAGATGCCAGC
Osteopontin For: TGAAGACCAGTATCCTGATGC XM_001496152 158
Rev: GCTGACTTGTTTCCTGACTG
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Mean values, representing the whole metacarpal region
of the tendon, were used for further analysis.
Frozen tendon samples were homogenized, and total
RNA was isolated, purified and transcribed into cDNA
using the RevertAid H Minus First Strand cDNA Syn-
thesis Kit (Thermo Fisher Scientific). RT-PCR was per-
formed with a 7500 Real Time PCR System (Applied
Biosystems, Foster City, USA) as described previously
[31]. Primers used are listed in Table 1, ACTB and
GAPDH were used as housekeeping genes for relative
quantification [32].
Statistical analysis
Using SPSS 20 statistics software (IBM, Ehningen,
Germany), Shapiro-Wilk tests were executed to test the
hypothesis of normal distribution of data. If this hypoth-
esis was not rejected, paired t-tests were performed to
compare MSC-treated tendons with the contralateral
controls, otherwise Wilcoxon-tests were performed.
P-values < 0.05 were considered significant.
Results
Clinical and imaging results
Induction of tendon lesions was demonstrable in all ten-
dons. No significant differences between the left and
right tendons were observed prior to cell injection, nei-
ther clinically nor in imaging. The procedures, including
the recovery from tendon biopsies, were tolerated well
using the medication described above.
During the first 2 weeks after cell injection, no signifi-
cant differences could be detected between the two
groups. However, there was a tendency that the
MSC-injected tendons showed prolonged clinical signs
of inflammation including swelling, heat, and pain. This
became manifest in the palpation scores, which
remained higher in the MSC group until week 6, with
the difference being significant at weeks 3 (p = 0.015)
and 4 (p = 0.022) (Fig. 1). Correspondingly, as seen in
ultrasonography, in the MSC group, the cross-sectional
area of the tendon was higher at weeks 3 (p = 0.016) and
4 (p = 0.022), the percentage of the tendon lesion was
Fig. 1 Clinical parameters: Diagrams displaying mean (± 2 SD) values of a palpation score and b lameness score over the whole follow-up period;
stars indicate significant differences between MSC-injected and contralateral tendons (p < 0.05); wk.: week post MSC injection
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Fig. 2 Ultrasonographic parameters: a representative transverse images obtained from the MSC-injected and the contralateral superficial digital
flexor tendons 3, 12 and 24 weeks after MSC injection; the respective tendon is indicated by the white line in the first upper image; note the
hypoechoic (dark) lesions within the tendons, which are decreasing over time. Diagrams displaying mean (± 2 SD) values of b ultrasonography
score and c percentage of the lesion within the cross-sectional area (CSA) of the tendon over the whole follow-up period; stars indicate
significant differences between MSC-injected and contralateral tendons (p < 0.05); wk.: week post MSC injection
Ahrberg et al. BMC Musculoskeletal Disorders  (2018) 19:230 Page 6 of 14
higher at weeks 4 (p = 0.042) and 6 (p = 0.039), and the
mean ultrasonography scores were higher at weeks 4
and 6, although the latter was not significant (Fig. 2). In
MRI, lesion volume at week 3 was higher in the MSC
group (p = 0.02) (Fig. 3).
However, after the first weeks, the clinical and imaging
findings improved and were more similar in both
groups. At week 24, based on the T2-weighted MRI
image series, the tendon lesions had resolved in 4 out of
6 cases in the MSC group and in 3 out of 6 cases in
Fig. 3 Magnetic resonance imaging parameters: a representative transverse T2-weighted images obtained from the MSC-injected and the
contralateral superficial digital flexor tendons 3, 12 and 24 weeks after MSC injection; the respective tendon is indicated by the white line in the
first upper image; note the lesions within the tendons, displaying high signal intensity at week 3, which is decreasing over time. Diagrams
displaying mean (± 2 SD) values of b lesion volume determined based on MRI images in mm3 and c lesion signal intensity obtained from MRI
images; star indicates significant difference between MSC-injected and contralateral tendons (p < 0.05); wk.: week post MSC injection; at week 24,
instead of n = 6 tendons per group, only 2 tendons are shown in the MSC group and 3 in the contralateral control group, due to the fact that
the remaining lesions were not detected anymore
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the control group. In the remaining lesions, the mean
lesion signal intensity was lower in the MSC group,
suggesting better tendon healing. Further clinical or
imaging parameters did not indicate improvement
compared to the controls. Correspondingly, macro-
scopic assessment after euthanasia did not reveal any
significant differences (Fig. 4).
Histology
Histologic findings largely reflected the clinical and im-
aging findings.
At week 3, hindlimb biopsies displayed a more fre-
quent occurrence of macrophages and perivasculitis,
resulting in a higher HE score, a lower percentage of
healthy crimp and a higher percentage of erythrocytes in
the MSC group, suggesting increased inflammation and
vascularization. However, these differences were not sig-
nificant, and the percentage of Fuchsin staining, the per-
centage of nuclei as well as collagen I immunostaining
were similar in both groups (Fig. 5).
At week 24, such differences did not exist anymore,
most stainings and parameters assessed being similar in
both groups (Fig. 6). However, the percentage of nuclei
was lower in the MSC group (p = 0.022), reflecting lower
cellularity (Fig. 5).
Musculoskeletal marker expression
All tendon markers including collagen 1A2, collagen
3A1, decorin, tenascin-C and scleraxis, as well as the pu-
tative early osteogenic marker osteopontin, were
expressed at detectable but variable levels (Fig. 7). Colla-
gen 2A1 was not expressed at detectable levels. No
significant differences could be observed between both
groups.
Discussion
Only few differences in tendon healing could be found
between MSC and control group at week 24. Differences
included that lesion resolution, as seen in T2w MRI, was
more advanced and cellularity was lower in MSC-treated
tendons at week 24. Furthermore, a transient increase in
inflammatory reaction and lesion size was observed in
the MSC-treated tendons during the first weeks. How-
ever, at week 24, clinical parameters, ultrasound, macro-
scopic and histological scores as well as musculoskeletal
marker expression were not different between treated
and control tendons. Based on the fact that MSC had
engrafted within the tendon lesions [22] and having de-
signed this study with a relatively long follow-up of
24 weeks, more significant differences between the two
groups had been expected based on the previous litera-
ture. Yet, the current data fail to provide distinctive evi-
dence to support the hypothesis that MSC improve
tendon healing.
The therapeutic approach pursued in the current study
was to locally inject adipose-derived MSC 3 weeks after
the induction of the tendon lesions. Applying the MSC
3 weeks after induction of the lesion is realistic, because
neither in human nor in equine medicine, the patient
would receive this autologous therapy within days after
the first onset of tendinopathy. Furthermore, the time
frame of 3 weeks between induction and treatment should
be adequate to support tendon healing, as Crovace et al.
found better histological results in the treated groups after
Fig. 4 Macroscopic parameters: a representative images of the dissected superficial digital flexor tendons at maximum lesion level, displaying
reddish and whitish injured areas within the tendon cross-section and b diagram displaying mean (± 2 SD) values of score points obtained at
macroscopic assessment; wk.: week post MSC injection
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choosing an interval of 3 weeks as well [28]. The latter as
well as most other studies in horses were conducted with
bone marrow-derived MSC [11, 16, 28, 33]. However, the
potential of adipose-derived cells is increasingly recog-
nized [34] and adipose-derived cells have also been used
for regenerative therapy of tendon lesions with good re-
sults [35, 36]. Furthermore, Burk et al. have shown that
adipose-derived MSC might be superior to bone
marrow-derived MSC regarding their potential to posi-
tively influence tendon matrix reorganization [37]. There-
fore, the decision to use adipose-derived MSC was
favorable, as adipose tissue is easily available with minor
surgery in both horses and humans compared to bone
marrow, and it remains unlikely that this cell source is the
reason for the absence of more significant improvements.
However, the MSC used in the current study had been la-
beled with SPIO, aiming to track the injected cells and
monitor their contribution to tendon healing at the same
time. Favorably, these SPIO-labeled MSC have been dem-
onstrated to integrate at the site of intralesional injection
[22], in accordance with a similar recent study [38]. It has
also been shown in vivo and in vitro that SPIO labeling in-
fluences neither stemness nor viability nor proliferation of
stem cells [39–42]. In an ovine osteoarthritis model using
Fig. 5 Histology parameters: Diagrams displaying mean (± 2 SD) values of a score points obtained at evaluation of hematoxylin-eosin (HE)
stained slides, b percentage of fuchsin staining representing uninjured or regenerated tendon tissue, c percentage of areas displaying healthy
crimp, d intensity of collagen I immunohistochemical (IHC) staining, e percentage of DAPI-stained nuclei indicating cellularity and f percentage
of erythrocytes indicating vascularization; star indicates significant difference between MSC-injected and contralateral tendons (p < 0.05); wk.: week
post MSC injection
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SPIO-labeled as well as SPIO-negative control MSC, no ad-
verse side effects of SPIO-labeled MSC have been demon-
strated [43]. However, current literature also suggests that
SPIO influences immune reactions in the surrounding tis-
sue and inhibits endothelial nitric oxide synthase [44, 45].
Therefore, it cannot be excluded that SPIO-labeling of the
MSC used in the current study might have compromised
their regenerative capacity and/or that released SPIO parti-
cles have triggered inflammation.
In this study, the tendon defect was created by a low
dose of collagenase injected with a 11 G bone marrow
aspiration needle. This large needle creates a mechanical
defect in addition to the enzymatical defect. The ration-
ale behind this approach was to combine the advantages
of the two most commonly used techniques, collagenase
injection and surgical induction, mimicking natural core
lesions more closely [46, 47]. This defect is therefore dif-
ferent from those in other studies using higher doses of
collagenase and ultrasound-guided injection via smaller
needles [28, 33, 48], which is likely to impact on respon-
siveness to MSC treatment.
Furthermore, the inclusion of adequate controls is cru-
cial. In this study, we chose to use the contralateral ten-
dons as intra-individual controls and to inject these
tendons with serum, as serum was used as vehicle to de-
liver the MSC in the treatment group. The vehicle for
MSC delivery should ideally maintain MSC viability prior
to injection and support their regenerative effect. While
for bone marrow MSC, bone marrow supernatant is most
commonly used, serum is a good alternative for other
MSC sources. However, saline or phosphate buffered sa-
line (PBS) have frequently been chosen for injection into
the control tendons [11, 33, 36], which is not indicative as
to whether any observed effect is due to MSC treatment
or the delivery vehicle. In this line, Geburek et al. used au-
tologous conditioned serum (ACS) without MSC for treat-
ment of naturally occurring tendinopathy and reported on
significant reduction of lameness and swelling in the ACS
group compared to saline [17]. This suggests that serum
itself may have beneficial effects on tendon healing. Con-
sequently, differences found in studies using PBS or saline
for control injections but serum or bone marrow super-
natant as MSC delivery vehicle [11, 33, 36] cannot without
doubt be attributed solely to the MSC. This could partly
explain that fewer beneficial effects were detected in the
current study, in which serum was used as a more rigor-
ous control regarding MSC efficacy.
The use of the contralateral tendon of the same animal
as control limits interference of inter-individual differences
with the results, reduces the numbers of animals required,
and has been described by several groups [28, 33, 38].
However, MSC could enter the blood circulation after in-
jection and migrate to other sites of injury or inflammation
as well, e.g. the contralateral defect, a process referred to as
homing [49, 50]. MSC have been shown to circulate in per-
ipheral blood after intralesional injection but had not been
found in untreated lesions so far [51, 52]. Yet, in the previ-
ously published part of the current study, MSC could be
shown to be present in the contralateral tendon lesions as
well, albeit in small numbers [22]. Based on that, the effect
of MSC distribution after intralesional injection might have
been underestimated when the current study was designed.
However, we still consider a strong impact on the results as
unlikely, as significantly fewer cells were found in the con-
trol lesions compared to the treated lesions.
Fig. 6 Histology images: Representative images from paraffin
sections stained with a hematoxylin-eosin, b Masson’s Trichrome, c
Picrosirius red, images obtained using polarized light, d anti-collagen
I antibody and alkaline phosphatase (red) detection kit and e DAPI
staining of nuclei (blue), the erythrocytes displaying
red autofluorescence
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Regarding sample and data analysis, while other
studies used only the maximum lesion zone for im-
aging assessment and the macroscopically affected
areas of the tendon for histological examination [28,
33, 48], we analyzed the whole metacarpal area of the
tendon. This may have hampered the detection of dif-
ferences potentially existing at the maximum lesion
sites only. However, this method is more rigorous as
it takes the whole longitudinal extension of the defect
into account, and there is no potential bias as
Fig. 7 Gene expression: Diagrams displaying mean (± 2 SD) values of relative gene expression of a collagen 1A2, b collagen 3A1, c decorin, d
scleraxis, e tenascin-C and f osteopontin, 24 weeks (wk) after MSC injection
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subjective identification of maximum lesion site is not
required.
Possibly elucidating which of the discussed factors and
differences between studies might most likely explain the
outcome, two previous studies are particularly interesting
for comparison. A recent carefully designed study, investi-
gating the effect of autologous adipose-derived MSC
suspended in inactivated serum in surgically created ten-
don lesions in the horse, over a follow-up period of
22 weeks, also revealed few improvements. The authors
did not find significant differences in histology, biochem-
ical or biomechanical parameters between MSC-treated
lesions and serum-injected contralateral control tendon
lesions, although hydroxylysylpyridinoline content in the
MSC group was closer to that of healthy tendon tissue,
potentially indicating better crosslinking [38]. In a differ-
ent study, the effect of bone marrow-MSC suspended in
bone marrow supernatant for treatment of naturally
occurring tendon lesions was investigated. After a
follow-up of 6 months post injection, treatment outcome
was favourable, with improved tissue structure, lower
cellularity, vascularity, water and glycosaminoglycan
content as well as matrix metalloproteinase-13 activity.
While it should be considered that controls were based on
saline injections, this study stands out because naturally
occurring tendon lesions were used, instead of artificially
creating them [11].
Considering the outcome of these two studies in line
with the current results, it appears most likely that MSC
are not capable to repair mechanically induced tendon
lesions, potentially due to the associated loss of tissue
that cannot be replaced adequately over a follow-up
period of 22 or 24 weeks, respectively. The choice of the
animal model is crucial in clinical translation and can
strongly impact on the results of preclinical studies. Al-
though we aimed to overcome the limitations of
collagenase-based and surgical lesion induction by com-
bining mild approaches of both techniques, the current
model might still not reflect naturally occurring tendino-
pathy. Therefore, taking advantage of the fact that horses
are equally prone to natural tendon disease as humans,
to use them as natural models as reported by Smith et
al. still represents the most reliable option- albeit not
without challenges [11]. With equal importance, it re-
mains possible that MSC are not significantly more ef-
fective than delivery vehicles such as bone marrow
supernatant or serum, even if inactivated, indicating that
this fundamental question has yet to be answered.
Yet, we observed significant differences during the
early healing phase between weeks 3 and 6, at which
clinical assessment and imaging suggested a stronger but
transient inflammatory reaction in MSC-treated tendons.
Although based on the current data, it cannot be ex-
cluded that SPIO might have induced this inflammatory
response, our results correspond to a previous study, in
which a transient increase in vascularization after injec-
tion of MSC was observed, while the latter were not
labeled with SPIO [35]. This could be part of the immu-
nomodulatory effects of MSC, which could be important
for debridement and lesion resolution and to prevent
fibrotic repair, thus there is reason to consider that this
transient inflammatory reaction could be beneficial [53].
However, except for the lower cellularity of treated
tendons, no distinctive evidence to support this hypoth-
esis was found in this study, thus further studies need to
elucidate the immunomodulatory effects of MSC in
tendon healing.
Conclusions
Intralesional injection of adipose-derived MSC led only
to minor improvements of tendon healing within the ob-
served time frame of 24 weeks, indicating that MSC
were not capable of repairing the mechanically disrupted
tissue within the tendon lesions during the observed
period. Future studies, ideally based on using naturally
occurring tendon lesions as a model and using the ad-
equate controls, still have to answer the fundamental
question whether the effect of MSC is superior to that of
biologically active body fluids such as serum. However,
we observed that MSC induced a transient inflammation
during early healing, followed by reduced cellularity in
treated tendons at week 24, which suggests a modulatory
effect warranting further investigations.
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